SCHEMBL7045240

SCHEMBL7045240

Cc1ccc(-c2cccnc2-c2ccc(S(C)(=O)=O)c(F)c2)cc1C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 5/20 0.44
NR1H3 Q13133 5/20 0.44
PTGS2 P35354 3/20 0.42
PTGS1 P23219 2/20 0.42
ALOX5AP P20292 5/20 0.39
FEN1 P39748 5/20 0.39
SCN5A Q14524 1/20 0.39
SCN9A Q15858 1/20 0.39
KIF11 P52732 1/20 0.38
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
TRPV1 Q8NER1 1/20 0.37
KMO O15229 1/20 0.37
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
ABCB11 O95342 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7044133 0.91 NR1H2 (0.44) NR1H2NR1H3PTGS2PTGS1ALOX5AP
SCHEMBL6729428 0.90 FEN1 (0.41) NR1H2NR1H3PTGS2PTGS1ALOX5AP
SCHEMBL7048786 0.89 PTGS2 (0.47) PTGS2PTGS1ALOX5APFEN1PIK3CD
SCHEMBL7537379 0.88 PTGS2 (0.47) PTGS2PTGS1ALOX5APFEN1PIK3CD
SCHEMBL7041595 0.85 PTGS2 (0.47) NR1H2NR1H3PTGS2PTGS1ALOX5AP
SCHEMBL7044091 0.84 PTGS2 (0.50) PTGS2PTGS1ALOX5APFEN1KMO
SCHEMBL7041942 0.84 PTGS2 (0.43) PTGS2PTGS1ALOX5APFEN1PIK3CD
SCHEMBL7046231 0.84 SYK (0.40) NR1H2NR1H3PTGS2PTGS1ALOX5AP
SCHEMBL7540499 0.84 PTGS2 (0.48) NR1H2NR1H3PTGS2PTGS1ALOX5AP
SCHEMBL7546410 0.84 PTGS2 (0.49) NR1H2NR1H3PTGS2PTGS1ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 NR1H2 282/4885NR1H3 570/4885PTGS2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.